Literature DB >> 24487392

Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells.

Hesham Basma1, Yoko Gunji, Shunichiro Iwasawa, Amy Nelson, Maha Farid, Jun Ikari, Xiangde Liu, Xingqi Wang, Joel Michalski, Lynette Smith, Javeed Iqbal, Radwa El Behery, William West, Sowmya Yelamanchili, Deborah Rennard, Olaf Holz, Kai-Christian Mueller, Helgo Magnussen, Klaus Rabe, Peter J Castaldi, Stephen I Rennard.   

Abstract

Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) eliminates many epigenetic modifications that characterize differentiated cells. In this study, we tested whether functional differences between chronic obstructive pulmonary disease (COPD) and non-COPD fibroblasts could be reduced utilizing this approach. Primary fibroblasts from non-COPD and COPD patients were reprogrammed to iPSCs. Reprogrammed iPSCs were positive for oct3/4, nanog, and sox2, formed embryoid bodies in vitro, and induced teratomas in nonobese diabetic/severe combined immunodeficient mice. Reprogrammed iPSCs were then differentiated into fibroblasts (non-COPD-i and COPD-i) and were assessed either functionally by chemotaxis and gel contraction or for gene expression by microarrays and compared with their corresponding primary fibroblasts. Primary COPD fibroblasts contracted three-dimensional collagen gels and migrated toward fibronectin less robustly than non-COPD fibroblasts. In contrast, redifferentiated fibroblasts from iPSCs derived from the non-COPD and COPD fibroblasts were similar in response in both functional assays. Microarray analysis identified 1,881 genes that were differentially expressed between primary COPD and non-COPD fibroblasts, with 605 genes differing by more than twofold. After redifferentiation, 112 genes were differentially expressed between COPD-i and non-COPD-i with only three genes by more than twofold. Similar findings were observed with microRNA (miRNA) expression: 56 miRNAs were differentially expressed between non-COPD and COPD primary cells; after redifferentiation, only 3 miRNAs were differentially expressed between non-COPD-i and COPD-i fibroblasts. Interestingly, of the 605 genes that were differentially expressed between COPD and non-COPD fibroblasts, 293 genes were changed toward control after redifferentiation. In conclusion, functional and epigenetic alterations of COPD fibroblasts can be reprogrammed through formation of iPSCs.

Entities:  

Keywords:  COPD; IPSCs; miRNA; microarray

Mesh:

Substances:

Year:  2014        PMID: 24487392      PMCID: PMC3949084          DOI: 10.1152/ajplung.00255.2013

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  44 in total

1.  Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate.

Authors:  F Liu; J K Killian; M Yang; R L Walker; J A Hong; M Zhang; S Davis; Y Zhang; M Hussain; S Xi; M Rao; P A Meltzer; D S Schrump
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

Review 2.  Myofibroblasts. II. Intestinal subepithelial myofibroblasts.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-08

3.  [Cyclooxigenase-2 levels are increased in the lung tissue and bronchial tumors of patients with chronic obstructive pulmonary disease].

Authors:  Jordi Roca-Ferrer; Laura Pujols; Carlos Agusti; Antoni Xaubet; Joaquim Mullol; Josep M Gimferrer; César Picado
Journal:  Arch Bronconeumol       Date:  2011-07-27       Impact factor: 4.872

4.  Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema.

Authors:  Laurent Plantier; Sylvain Marchand-Adam; Joëlle Marchal-Sommé; Guy Lesèche; Michel Fournier; Monique Dehoux; Michel Aubier; Bruno Crestani
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2004-12-03       Impact factor: 5.464

5.  3-Nitrotyrosine inhibits fibroblast-mediated collagen gel contraction and chemotaxis.

Authors:  H Sugiura; X Liu; T Ichikawa; M Ichinose; S I Rennard
Journal:  Eur Respir J       Date:  2009-05-14       Impact factor: 16.671

6.  Generation of human induced pluripotent stem cells from dermal fibroblasts.

Authors:  W E Lowry; L Richter; R Yachechko; A D Pyle; J Tchieu; R Sridharan; A T Clark; K Plath
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-15       Impact factor: 11.205

7.  Induced pluripotent stem cells from a spinal muscular atrophy patient.

Authors:  Allison D Ebert; Junying Yu; Ferrill F Rose; Virginia B Mattis; Christian L Lorson; James A Thomson; Clive N Svendsen
Journal:  Nature       Date:  2008-12-21       Impact factor: 49.962

8.  A random variance model for detection of differential gene expression in small microarray experiments.

Authors:  George W Wright; Richard M Simon
Journal:  Bioinformatics       Date:  2003-12-12       Impact factor: 6.937

9.  Lung fibroblasts from patients with emphysema show markers of senescence in vitro.

Authors:  K-C Müller; L Welker; K Paasch; B Feindt; V J Erpenbeck; J M Hohlfeld; N Krug; M Nakashima; D Branscheid; H Magnussen; R A Jörres; O Holz
Journal:  Respir Res       Date:  2006-02-21

10.  Putative roles of circulating resistin in patients with asthma, COPD and cigarette smokers.

Authors:  Sana S Al Mutairi; Olusegun A Mojiminiyi; Aida Shihab-Eldeen; Tahani Al Rammah; Nabila Abdella
Journal:  Dis Markers       Date:  2011       Impact factor: 3.434

View more
  3 in total

Review 1.  Coming to terms with tissue engineering and regenerative medicine in the lung.

Authors:  Y S Prakash; Daniel J Tschumperlin; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-07       Impact factor: 5.464

Review 2.  Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?

Authors:  Nurdan Kokturk; Fatma Yıldırım; Pınar Yıldız Gülhan; Yeon Mok Oh
Journal:  Am J Stem Cells       Date:  2018-08-01

Review 3.  Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target.

Authors:  Srikanth Karnati; Michael Seimetz; Florian Kleefeldt; Avinash Sonawane; Thati Madhusudhan; Akash Bachhuka; Djuro Kosanovic; Norbert Weissmann; Karsten Krüger; Süleyman Ergün
Journal:  Front Cardiovasc Med       Date:  2021-04-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.